JPRN-UMIN000003270已完成2 期
Multicenter Phase II study of erlotinib therapy in recurrent or advanced non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutation - Phase II Study of erlotinib in EGFR mutation Non-Small Cell Lung Cancer.
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 26 人开始时间: 2010年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis. 2)Patients with massive pleural or pericardial effusion ,or ascites. 3)Patients with active severe infections. 4)Cases with past history of administration of HER related agents. [ex) gefitinib, lapatinib, trsutuzumab, cetuximab] 5)Impossible cases with oral administration. 6)Patients with active opthalmological disease. 7) Patients with active concomitant malignancy. 8) Patients with symptomatic brain metastasis. 9)Patients with double cancer. 10)Patients with uncontrollabe diabetes mellitus. 11)Patients with uncontrollable complications. 12)Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
2 期
Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.on-small cell lung cancerJPRN-UMIN000014299Dept. of Respiratory Medicine, Osaka Police Hospital7
已完成
2 期
Phase II study of erlotinib monotherapy for patients with untreated advanced non-small cell lung cancer, poor performance status and positive EGFR mutation status (OSAKA-LCSG1304)JPRN-UMIN000011473OSAKA-LCSG23
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
招募中
2 期
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27